Mass Medical Angels

What Mass Medical Angels does

Mass Medical Angels (MA2), founded in 2010 and headquartered in Boston, Massachusetts, is a private, volunteer-driven seed-stage angel investment group exclusively focused on life science and healthcare investments. The organization provides financing and mentoring to early-stage life science companies across medical devices, therapeutics, diagnostics, health services, health information technologies, and healthcare-relevant laboratory instruments. MA2 sources deals through member networks, technology transfer offices, an entrepreneur advisory board, and direct business plan submissions via the GUST platform, conducting monthly screening committees and bi-monthly member meetings at research and life science facilities in the Boston area.

The group's investment model is structurally distinct from institutional seed funds: MA2 charges no management fees and no override fees, with all work performed on a pro bono basis by carefully vetted accredited investor members who include researchers, clinicians, venture capitalists, executives, consultants, engineers, bankers, and attorneys with deep health sciences expertise. Individual check sizes typically range from $250,000 to $3 million per company, with MA2 willing to provide all or part of a round and to co-invest alongside other angel groups and venture funds. The target return profile is 5x within 5 years (approximately 40% annual ROI), realized through acquisitions or technology licensing rather than ongoing cash distributions.

MA2 has built a portfolio of at least 17 named companies including Daktari Diagnostics, Sage Science, Life Image, Momelan Technologies, Thermalin Diabetes, Polytouch Medical, Lantos Technologies, Bliss Healthcare, Annovation BioPharma, Avaxia Biologics, Diffinity Genomics, Sialix, ZetrOZ, JB Therapeutics, AesRx, InfoBionic, and Parsagen Diagnostics, spanning diagnostics, devices, therapeutics, and digital health. Recent activity includes a $1.2 million seed round in Entirety Biomedical led by NuFund Venture Group and participation in an $8 million seed financing for Cayuga Biotech alongside a $3 million Defense Health Agency award. The Executive Board is led by Founder and Executive Director Richard Anders, Co-Founders Carl Berke and Pushwaz Virk, and Director Roger Kitterman, with Richard Berenson as Director and Penny Rossano chairing the Screening Committee.

Name

Mass Medical Angels

Legal name

Mass Medical Angels

Website

https://massmedangels.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

Mass Medical Angels (MA2) is a Boston-based, volunteer-driven seed-stage angel investment group exclusively focused on life sciences and healthcare, providing $250K–$3MM checks and mentoring to early-stage medical device, therapeutic, diagnostic, health IT, and lab equipment companies.

Ownership category

akta.pro rank

Product category

Angel Investment Services

NAICS

Open-End Investment Funds (525910), Other Financial Vehicles (525990)

SIC

Investment Advice (6282)

akta.pro primary industry

Micro-VC & Angel Funds (FSANAAAI)

Keywords

• Angel investment group
• Seed stage funding
• Life sciences venture
• Healthcare capital
• Early stage investing

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Revenue model

1. Investment Returns: MA2 generates returns through capital appreciation of portfolio companies, realized via acquisition or technology license by other companies. Target return is 5x within 5 years (approximately 40% annual ROI). The group invests in companies looking to raise $250K to $3MM in seed funding.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Mass Medical Angels is a seed-stage angel investment group that provides early-stage financing ($250,000 to $3 million per company) and mentoring exclusively to life science and healthcare companies. The group invests in medical devices, therapeutics, diagnostics, health services, health information technologies, and healthcare-relevant laboratory equipment, with a target of 5x return within 5 years. Members individually deploy capital after collective screening committee review and due diligence.

Product overview

Mass Medical Angels (MA2) is a seed-stage angel investment group exclusively focused on life science and healthcare investments. It is not a product company; rather, it provides financing and mentoring services to early-stage life-science companies. The organization facilitates investments in medical devices, therapeutics, diagnostics, health services, health information technologies, and relevant research-related tools including laboratory equipment. MA2 offers its investment services through screening committees (Therapeutics screening and Device screening), due diligence processes, and an entrepreneur advisory board. The group typically invests between $250,000 to $3 million in companies looking to raise seed funding, with a target of achieving 5x returns within 5 years.

Differentiator

Problem solved

Functional benefit

Products and services

• Seed Investment Funding Seed-stage equity investment funding of typically $250,000 to $3,000,000 per company, with initial investments between $200,000 and $500,000 and milestone-based follow-on capital. Targeted at early-stage life science and healthcare companies (medical devices, therapeutics, diagnostics, health services, health IT, laboratory equipment) seeking capital to reach proof-of-concept, attract further institutional funding, reach positive cash-flows, or be acquired. Target return is 5x within 5 years.
• Portfolio Company Mentoring & Advisory Mentoring and advisory support provided to portfolio companies by vetted MA2 members who serve as sounding boards, advisors, experts, and in some cases officers. Members bring deep life science expertise as researchers, clinicians, venture capitalists, executives, consultants, engineers, bankers, and attorneys, with access to Boston healthcare supercluster institutions for additional advisors, deal flow, and resources.
• Therapeutics & Device Screening Committees Monthly screening committees that review inbound business plans from prospective portfolio companies, with separate Therapeutics and Device screening tracks. Selected companies are invited to present at bi-monthly MA2 member meetings, after which due diligence teams are formed for promising investments. Plans are submitted via the GUST platform.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered core and minor.

• Mintz LevincoreImplementation/ SI/ Consulting PartnerLaw firm founded in 1933 with 500+ attorneys representing diverse international clients including entrepreneurs, research scientists, investors, start-ups, and medical institutions. Provides legal services to MA2 and portfolio companies.
• Baker TillycoreImplementation/ SI/ Consulting PartnerTop ten advisory tax and assurance firm dedicated to customized business solutions. Provides accounting and advisory services to MA2 and portfolio companies.
• Mass MediccoreGTM or Marketing PartnerMassachusetts Medical Device Industry Council is the voluntary grassroots association of medical device manufacturers in the Commonwealth. The only organization in New England dedicated solely to promoting medical device industry interests.
• Mass BiocoreGTM or Marketing PartnerMassachusetts Biotechnology Council, founded in 1985, provides services and support for Massachusetts biotechnology industry. Committed to advancing development of critical new science, technology and medicines.
• Gill Fishman DesignminorImplementation/ SI/ Consulting PartnerFull service brand consulting and design services firm that helps clients create, build and maintain successful brand equity and marketing communications.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Life Science Angels: Bay Area-based seed-stage angel group exclusively focused on life sciences and healthcare investments. Directly comparable to MA2 in mandate (early-stage life science deals), check size, member-driven structure, and domain expertise requirements.
• Mid-Atlantic Bio Angels: Regional angel investor group focused on early-stage biotech, medical device, and health IT companies. Similar to MA2 in screening-committee structure, sector focus, and seed-stage investment thesis, though Mid-Atlantic-focused rather than New England.
• Tech Coast Angels: One of the largest U.S. angel networks with dedicated life sciences screening. Comparable in accredited-investor-only structure, screening committees, and seed-stage focus, though with a Southern California geographic base and broader tech mandate alongside healthcare.
• Golden Seeds: Angel network with a dedicated healthcare and life sciences track alongside broader sectors. Comparable in member-driven accredited-investor model, seed-stage check sizes, and structured screening/presentation process, but with a national (not Boston-centric) footprint.

Regional players

• Boston Harbor Angels: Boston-area angel investing group that invests in early-stage technology and life sciences companies. Geographic peer to MA2 with overlapping deal flow and similar structured screening, though with a broader tech mandate rather than MA2's exclusive healthcare focus.
• Sand Hill Angels: Silicon Valley angel group that includes healthcare/life sciences among its investments. Comparable structured-angel model with monthly screening and member-driven due diligence, though primarily serving Bay Area startups rather than East Coast.

Others

• Angel Capital Association (ACA): Trade association for angel investor groups in North America. Not a direct competitor but a peer/ecosystem participant that MA2-style groups often belong to; useful as a benchmark for angel group operating practices and deal-sharing infrastructure.
• New England Venture Capital Association: Regional industry association representing venture capital firms in New England. Not a direct peer but a relevant ecosystem organization for sourcing co-investment partners and benchmarking deal activity in MA2's core geography.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments29 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mass Medical Angels